You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Montelukast moderately decreased asthma symptoms in children with persistent asthma

https://doi.org/10.1136/ebm.7.3.77

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Pediatrics 108, e48. Knorr B, Franchi LM, Bisgaard H, et al. . Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.. Sep;. :. ..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In children with persistent asthma, is montelukast a well tolerated and effective therapeutic option?

    Design

    Randomised {allocation concealed*}†, blinded (patients, clinicians, and {data collectors}†),* placebo controlled trial with 12 weeks of follow up.

    Setting

    93 centres in Africa, Australia, Europe, North America, and South America.

    Patients

    689 children who were 2 to 5 years of age (mean age 4 y, 59% boys, 56% white), had ≥ 3 episodes of asthma symptoms in the previous year, had a total asthma symptom score ≥ 1 (of 24) for ≥ 8 days during the 2 week placebo baseline period, and used β agonists for ≥ 8 days during the placebo baseline period. Exclusion criteria included asthma intubation and emergency department treatment or admission …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • ↵‡ p Values provided by author.

    • Source of funding: Merck Research Laboratories.

    • For correspondence: Dr B Knorr, Respiratory & Allergy, Merck Research Laboratories, Rahway, NJ, USA.